Quantcast

Latest Castle Biosciences Inc Stories

2014-05-31 08:21:15

New DecisionDx-EC multi-analyte test data presented at ASCO 2014 CHICAGO, May 31, 2014 /PRNewswire/ -- Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy. The results were reviewed in a poster presentation at the 50(th) Annual Meeting of the American Society of Clinical...

2014-05-14 16:29:17

DecisionDx-Melanoma identifies patients with negative sentinel lymph node biopsies who are at high risk of metastasis FRIENDSWOOD, Texas, May 14, 2014 /PRNewswire/ -- Castle Biosciences Inc. announced today that abstracts reporting additional clinical validation data for two of its molecular tests -- one focused on melanoma and the other on esophageal adenocarcinoma -- will be presented at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30-June 3,...

2014-05-06 08:34:50

Enables physicians to pursue more effective treatment plans for patients who are chemoradiation resistant CHICAGO, May 6, 2014 /PRNewswire/ -- Castle Biosciences Inc. announced that data from two clinical validation studies of its DecisionDx-EC multi-biomarker test were reviewed in an oral presentation at the Digestive Disease Week (DDW) Annual Meeting. The data show that the test accurately predicts response to pre-surgical chemoradiation therapy (CTRT) in patients with esophageal...

2014-04-29 08:35:53

Presentation at the American Association for Thoracic Surgery 94th Annual Meeting TORONTO, April 29, 2014 /PRNewswire/ -- Castle Biosciences Inc. announced that data from two validation studies of its DecisionDx-Mesothelioma molecular test were presented at the American Association for Thoracic Surgery 94(th) Annual Meeting. According to the data, the test accurately predicted survival in metastatic pleural mesothelioma (MPM) patients based on the gene expression profile signature...

2014-03-22 20:20:22

Data presented at the Latest in Dermatology Research Symposia session of 72nd Annual Meeting of the American Academy of Dermatology DENVER, March 22, 2014 /PRNewswire/ -- Castle Biosciences Inc. today announced study results showing its gene expression profile (GEP) test (DecisionDx-Melanoma) can identify primary cutaneous (skin) melanoma tumors that are likely to metastasize in patients who had a negative sentinel lymph node biopsy. The data are being presented at the Latest in...

2014-02-04 12:27:40

Program goal is improved understanding of individual risk for recurrence in patients diagnosed with early stage melanoma FRIENDSWOOD, Texas, Feb. 4, 2014 /PRNewswire/ -- Castle Biosciences Inc., a leading developer of diagnostic and prognostic tests for rare cancers, today announced the launch of an educational program dedicated to the information needs of Stage I and II skin (cutaneous) melanoma patients and their caregivers. The program kicks off with the launch of an animated...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related